Fulcrum Therapeutics, Inc.

NASDAQ:FULC

4.55 (USD) • At close December 24, 2024
Bedrijfsnaam Fulcrum Therapeutics, Inc.
Symbool FULC
Munteenheid USD
Prijs 4.55
Beurswaarde 245,421,085
Dividendpercentage 0%
52-weken bereik 2.86 - 13.7
Industrie Biotechnology
Sector Healthcare
CEO Mr. Alexander C. Sapir
Website https://www.fulcrumtx.com

An error occurred while fetching data.

Over Fulcrum Therapeutics, Inc.

Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy; and FTX-6058,

Vergelijkbare Aandelen

BioXcel Therapeutics, Inc. logo

BioXcel Therapeutics, Inc.

BTAI

0.351 USD

Heron Therapeutics, Inc. logo

Heron Therapeutics, Inc.

HRTX

1.58 USD

HilleVax, Inc. logo

HilleVax, Inc.

HLVX

1.87 USD

Absci Corporation logo

Absci Corporation

ABSI

3.01 USD

ALX Oncology Holdings Inc. logo

ALX Oncology Holdings Inc.

ALXO

1.83 USD

Athira Pharma, Inc. logo

Athira Pharma, Inc.

ATHA

0.542 USD

C4 Therapeutics, Inc. logo

C4 Therapeutics, Inc.

CCCC

3.87 USD

OraSure Technologies, Inc. logo

OraSure Technologies, Inc.

OSUR

3.69 USD

EyePoint Pharmaceuticals, Inc. logo

EyePoint Pharmaceuticals, Inc.

EYPT

7.33 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)